stockrow
Friday 6 November 2026
Export BEAM’s income statement to Excel — free account
Beam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
26.09
0.22
+0.85%
Follow BEAM
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(8.11%) | (5.77%) | (8.18%) | (11.29%) | |
Piotroski F-Score |
4 | 3 | 3 | 3 | |
| (6.19%) | (4.48%) | (6.23%) | (8.40%) | ||
ROIC |
0.00% | (438.41%) | (1,599.30%) | (2,676.86%) | |
Return on Tangible Assets |
(6.27%) | (5.10%) | (7.24%) | (10.04%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.64) | (3.72) | (3.57) | (3.80) | |
Free Cash Flow |
(360.05) | (383.84) | (372.77) | (398.24) | |
Capital Expenditures |
(14.95) | (14.11) | (13.39) | (9.59) | |
| Other line items | |||||
Cash ROIC |
(14.50%) | (15.50%) | (16.06%) | (18.99%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
293.12% | 253.23% | 261.91% | 278.91% | |
Selling, General and Administrative Expense of Revenue |
81.45% | 73.35% | 80.36% | 88.77% | |
Share Based Compensation of Revenue |
67.44% | 52.80% | 52.24% | 52.73% | |
Operating CF/Net income |
4.31 | 5.60 | 4.15 | 3.59 | |
Depreciation/Fixed assets |
0.06 | 0.07 | 0.10 | 0.12 | |
Capex/Depreciation |
(2.36) | (1.87) | (1.41) | (0.88) | |
Revenue per Share |
1.41 | 1.59 | 1.50 | 1.40 | |
Operating CF per Share |
(3.49) | (3.58) | (3.44) | (3.71) | |
Capex per Share |
(0.15) | (0.14) | (0.13) | (0.09) | |
Capex to Sales |
0.11 | 0.09 | 0.09 | 0.07 |
Columns are period end dates · fundamentals updated 5 Nov 2026